Initially developed at Yale University, our novel screening test uses droplet digital PCR (ddPCR) and methylation discrimination to detect signals of beta cell apoptosis—the death of insulin-producing cells. This biomarker offers an early window into beta cell health and potential diabetes risk.
By combining this innovative biomarker with C-peptide testing to assess insulin production, insulin testing, and HbA1c testing to measure average blood glucose, we provide a comprehensive screening assessment of metabolic health and diabetes risk.
Identifying risk early creates an opportunity for timely intervention, which may help delay disease progression and improve long-term health outcomes.
This screening test provides a snapshot of your current diabetes risk. A negative result does not rule out the possibility of developing diabetes in the future.